Introduction
============

Craniosynostosis is the pathologic fusion of calvarial bones and occurs in approximately 1/2500 live births. A genetic component to the disease is likely given a 7%--10% recurrence risk.[@b1-grsb-6-2012-081] Craniosynostosis cases can be classified into two categories, syndromic and non-syndromic forms. Over one hundred forms of syndromic craniosynostosis have been identified, including Apert, Crouzon, Muenke, Pfeiffer, and Saethre-Chotzen syndromes, which are associated with various phenotypic manifestations in addition to premature fusion of calvarial sutures.[@b2-grsb-6-2012-081] In contrast, individuals with non-syndromic craniosynostosis lack non-sutural phenotypes.

Mutations in genes such as *FGFR*1*-*3*, TWIST*1*, EFNB*1*, FBN*1*, MSX*2*, RAB*23*, RECQL*4, and *TGFBR*1*-*2 have been associated with syndromic craniosynostosis,[@b3-grsb-6-2012-081] whereas markers for the pathogenesis of non-syndromic forms of the disease have proven more difficult to identify.[@b3-grsb-6-2012-081]--[@b5-grsb-6-2012-081] Improving our understanding of what causes non-syndromic craniosynostosis remains an important endeavor considering non-syndromic forms of this disease account for approximately 85% of all cases. In fact, recent reports suggest the incidence of all forms of non-syndromic craniosynostosis, especially metopic cases, is on the rise.[@b6-grsb-6-2012-081],[@b7-grsb-6-2012-081] Generally, half of non-syndromic cases involve premature fusion of the sagittal suture, whereas premature coronal and metopic suture closure occurs in 22% and 15% of cases, respectively.[@b8-grsb-6-2012-081]

The differences between syndromic and non-syndromic forms of craniosynostosis including clinical features, classified mutations, and incidence suggest that these two forms of craniosynostosis are unique. In this paper, another characteristic difference between syndromic and non-syndromic craniosynostosis is investigated, namely sex predilection. In non-syndromic craniosynostosis, males have an overall higher frequency of developing craniosynostosis than females. In isolated sagittal and metopic craniosynostosis there is a near four-fold increased incidence among males, whereas in coronal cases the male/female ratio is nearly even.[@b8-grsb-6-2012-081] The observation that maleness has been shown to predispose individuals to craniosynostosis suggests that if transcriptomic changes are driving this predilection, then females with male-patterned expression of select disease- related genes may be predisposed to developing non-syndromic craniosynostosis.

To this end, transcriptomic arrays from a large cohort of individuals with non-syndromic craniosynostosis were analyzed in order to identify sex-related changes in gene expression that predispose individuals to developing this disease. First, differential gene expression between control males and females was compared against differential gene expression between males and females with craniosynostosis in order to create divergent and convergent gene sets. Sex related expression was defined as divergent in craniosynostosis cases when sex differences were not observed in controls and convergent when sex differences present in controls were absent in cases ([Fig. 1](#f1-grsb-6-2012-081){ref-type="fig"}). Next, the divergent and convergent gene expression of affected male and female cases was compared directly against sex-matched controls to confirm that the gain or loss of transcript expression was significantly different ([Fig. 1](#f1-grsb-6-2012-081){ref-type="fig"}). Results from these comparisons identified sex-dependant disturbances to genes involved in Ca^2+^-mediated phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling as key targets that predispose females to craniosynostosis, whereas *TINAGL*1 expression plays a more important role in predisposing males to the disease by potentially disrupting TGF-β activity. More importantly, differential expression of genes related to these pathways can be directly linked to increased *RUNX*2 activity, a mechanism known to cause premature fusion of calvarial sutures.

Methods
=======

Informed consent
----------------

Written informed consent was obtained from all participants with single-suture craniosynostosis, whereas a waiver of consent was obtained from the Seattle Children's Hospital Institutional Review Board (IRB) for the anonymous control samples used in this study. This study is HIPAA compliant, and we obtained independent prospective IRB approval from each participating center, including Seattle Children's Hospital, Northwestern University in Chicago, Children's Heath Care of Atlanta, and St. Louis Children's Hospital.

Cell culture
------------

All primary osteoblast cell lines were derived from participants in a previously described craniosynostosis study.[@b9-grsb-6-2012-081] Subsets of the 249 cell lines included 50 controls and 100 sagittal, 50 coronal, and 49 metopic craniosynostosis cases. Craniosynostotic calvaria were obtained from discarded tissues during surgical reconstructive procedures, whereas control calvaria were obtained from discarded tissues from anonymous surgical or autopsy specimens. Harvested calvaria samples were then washed and expanded in Waymouth's media (Sigma: St. Louis, MO) supplemented with 2X Penicillin/Streptomycin/Fungizone (Hyclone: Logan, UT) and 10% heat-inactivated fetal bovine serum (FBS) (Hyclone: Logan, UT). Osteoblasts were grown at 37 °C, 5% CO~2~, and 99% humidity, trypsinized using 0.05% Trypsin (Hyclone: Logan, UT) upon reaching 75% confluence, counted and passaged at a cell density of 175,000 cells per 25 cm^2^.

Cell harvest and RNA isolation
------------------------------

Once the re-plated cells reached 75% confluence, they were photographed for quality control purposes, washed twice with 1X PBS, and trypsinized. An equal volume of media containing FBS was added after trypsin exposure, and cells were centrifuged at 200 × g for 10 minutes at 4 °C in nuclease free 15 mL conical tubes (Corning: Lowell, MA). Following a washing step, cells were centrifuged again at 200 × g for 10 minutes at 4 °C. RNA extraction from cell pellets was performed using the Roche High Pure miRNA Isolation Kit in accordance to the manufacturer's protocol (Roche: Indianapolis, IN). RNA was stored immediately in −80 °C and either analyzed by quantitative reverse transcriptase PCR (qRT-PCR) or submitted for microarray processing on dry ice.

Preparation of samples for quantitative real-time PCR
-----------------------------------------------------

cDNA was synthesized from total RNA using the High RevertAid First Strand cDNA Synthesis Kit (Fermentas: Glen Burnie, MD) according to the manufacturers protocol. Reactions were set up in duplicate with the following components in each well of an ABI microAMP Fast Optical 96-well Reaction Plate (Life Technologies: Carlsbad, CA), 10 μL 2X SensiMix SYBR low-ROX master mix (Bioline: London, UK), 2 μL primers (1--5 μM) (Sigma: St. Louis, MO), and 8 μL sample cDNA (1.25 ng/μL). All primers were designed using PrimerBank (<http://pga.mgh.harvard.edu/primerbank/>) to amplify the following targets: *CD*24 (NM_013230), *FBN*2 (NM_001999), *IGF*2*BP*3 (NM_006547), *PDE*1*C* (NM_005020), *RUNX*2 (NM_001024630), and *TINAGL*1 (NM_022164). Reaction plates were then sealed and centrifuged for 1 minute at 1,000 × g. qRT-PCR was performed on an Applied Biosystems ABI7500 Fast Real-Time PCR System (Life Technologies: Carlsbad, CA). Ct values were normalized to 18s expression (NR_003286) and relative differences in mRNA expression were compared between craniosynostosis cases and controls.

Validation of divergent CD24 expression by qRT-PCR
--------------------------------------------------

Quantitative real-time PCR was performed on 32 randomly selected primary cell lines (24 craniosynostosis cases and 8 controls). Eight coronal, eight metopic and eight sagittal cases comprised the twenty-four total craniosynostosis cases assayed. Within each group of eight, four females and four males were assayed in order to determine whether divergent expression was consistent among all craniosynostosis sub-types. Similarly, of the eight controls assayed, four were female and four were male.

qRT-PCR on cell lines expressing high *FBN*2, high *IGF*2*BP*3, and low *PDE*1*C*
---------------------------------------------------------------------------------

Quantitative real-time PCR was performed on primary cell lines in which microarray-based expression of both *FBN*2 and *IGF*2*BP*3 were in the top third of the entire cohort (n = 249), while maintaining *PDE*1*C* expression within the bottom third (n = 21; 17 craniosynostosis cases and 4 controls).

Microarray analysis
-------------------

Raw microarray data were pre-processed and normalized with Affymetrix^®^ Expression Console™ Software using RMA normalization (<http://affymetrix.com>). Microarray quality control metrics include the manufacturer's recommended guidelines: visual inspection of probe array images, proper ranking of hybridization and Poly-A controls, and area under the curve values for a receiver operating characteristic plot comparing the positive control and negative control signal values. Other microarray quality control metrics were generated with the Bioconductor R package named "aroma.affymetrix" and included the relative log expression (RLE) values (assessing the potential spread or shifting of expression values), and the normalized unscaled standard errors (NUSE) (assessing variability of genes across arrays) (R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, <http://www.R-project.org>).[@b10-grsb-6-2012-081] All microarray data have been deposited in the Gene Expression Omnibus Database under accession number GSE27976 (<http://www.ncbi.nlm.nih.gov/geo/>).

Statistical analysis
--------------------

From the normalized data, genes with significant evidence for differential expression were identified using the limma package[@b11-grsb-6-2012-081] in Bioconductor.[@b12-grsb-6-2012-081] *P*-values were calculated with a modified *t*-test in conjunction with an empirical Bayes method to moderate the standard errors of the estimated log-fold changes. *P*-values were adjusted for multiplicity using Bioconductor's implementation of the Benjamini-Hochberg[@b13-grsb-6-2012-081] *P*-value adjustment method, which allows for selecting statistically significant genes while controlling the estimated false discovery rate.

Results
=======

Identification of divergent, convergent, and shared transcripts
---------------------------------------------------------------

249 primary osteoblast cell lines were developed from individuals with non-syndromic craniosynostosis and controls. Transcriptomic analysis of these cell lines identified sex-based differential gene expression that persisted during in vitro culture. Divergent genes unique to craniosynostosis were highly dependent on the synostosis sub-type, in that the number of sex-related, craniosynostosis-related transcripts was variable among coronal, metopic, and sagittal cases ([Table 1](#t1-grsb-6-2012-081){ref-type="table"}). In fact, only *CD*24 downregulation was considered significant overall three sutures ([Supplemental Table 1](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). Divergent *CD*24 expression was verified by qRT-PCR ([Supplemental Table 2](#s1-grsb-6-2012-081){ref-type="supplementary-material"}), confirming female cases had lower expression of *CD*24 than their male counterparts (fold change = −2.8, *P* = 0.06) with no significant differences seen between female and male controls (*P* = 0.61). Expression of *COL*11*A*1, *F*2*R*, *FAM*38*B*, *PLA*2*G*16, and *VCAM*1 was consistent among coronal and metopic cases, whereas significant expression of all other divergent transcripts was unique to one specific synostosis sub-type ([Supplemental Table 1](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). These data suggest that divergent sex-related gene expression in non- syndromic craniosynostosis is generally suture-dependent, and that divergent expression is most prominent in metopic cases since 99 transcripts were identified in this synostosis sub-type alone ([Table 1](#t1-grsb-6-2012-081){ref-type="table"}).

Unlike the divergent gene set, transcript expression within the convergent gene set was not dependent on the synostosis sub-type. This was evidenced by the fact that sex-related expression in 30 of the 32 convergent genes was consistent among all three synostosis sub-types ([Table 2](#t2-grsb-6-2012-081){ref-type="table"}). These results suggest that losing sex-based differences in transcriptional activity is consistent among affected individuals and is therefore independent of synostosis sub-type. Like the convergent gene set, transcript expression within the shared gene set was also not dependent on the synostosis sub-type. This was evidenced by the fact that in 20 of the 22 genes were shared among controls and all three forms of craniosynostosis ([Table 2](#t2-grsb-6-2012-081){ref-type="table"}). Furthermore, of the 20 genes shared among controls and all three craniosynostosis types, all 20 are sex-linked ([Supplemental Table 3](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). *GAGE*12*C* and a pseudogene of *AARSD*1 are the only X-linked genes in the shared set and are upregulated in females, whereas the remaining 18 Y-linked genes are upregulated in males ([Supplemental Table 3](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). By definition, the shared gene set includes genes in which expression was found to be differentially regulated between control males and females as well as case males and females. While this gene set may not provide insight in differential sex-related gene expression between cases and controls, it does validate our methodology in that differential expression of X- and Y-linked genes is consistent with respect to the sex of the individual.

Divergent genes differentially expressed from controls
------------------------------------------------------

The identification of divergent synostotic expression may provide insight into genes that shape the observed sex frequencies found in the disease state, however, it is also of interest to investigate whether divergent synostotic expression differs significantly from control populations. To this end, affected individuals were separated based on sex and compared against their respective sex-matched controls to determine whether divergent synostotic gene expression differed from controls to a significantly large extent (\|fold change\| \>1.5, *P* \< 0.05) ([Supplemental Table 4](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). *VCAM*1 was the only divergent transcript differentially expressed between sex-matched cases and controls to a large and significant extent in males with all forms of non-syndromic craniosynostosis ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). It is also worth noting that increased *VCAM*1 expression was observed in female coronal and sagittal cases compared to female controls as well, suggesting that *VCAM*1 upregulation may not be a male-specific craniosynostotic effect ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}).

Convergent genes differentially expressed from controls
-------------------------------------------------------

Analogous to the analysis performed on the divergent gene set, affected individuals were separated based on sex and compared against sex-matched controls to determine whether convergent gene expression in craniosynostosis differed from controls to a significantly large extent. It was expected that transcript expression would be more consistent between sex-matched cases and controls based on the fact that convergent expression was independent of synostosis sub-type. Four convergent genes (*IGF*2*BP*3*, FBN*2*, PDE*1*C* and *TINAGL*1) lost significantly large differences in expression between males and females in all cases, while still maintaining large (\|fold change\| \> 1.5) and significant (*P* \< 0.05) differences in expression from sex-matched controls ([Fig. 2](#f2-grsb-6-2012-081){ref-type="fig"}). Compared to sex-matched controls, female cases had lower expression of *PDE*1*C* and higher expression of *IGF*2*BP*3 and *FBN*2, while male cases had decreased expression of *TINAGL*1. The identification of these four transcripts where sex-specific expression was lost, yet differential expression from sex-matched controls was maintained, may indicate critical pathogenic roles for these genes. In other words, male and female cases are becoming more similar to each other, while simultaneously distancing themselves from control-like expression patterns where sex differences once existed. Finally, all four of these transcripts are capable of modulating *RUNX*2 expression/activity. Because of this, the dataset was mined to determine whether sex-based differences in *RUNX*2 expression were present. The search revealed *RUNX*2 to be a significantly convergent transcript that did not meet our threshold cutoff (\|% change\| \< 50%), as female controls expressed 32% more *RUNX*2 than their male counterparts (*P* \< 0.05). No significant sex-based differences were observed when comparing males and females in each of the craniosynostosis sub-types.

Quantitative real-time PCR on cases with high *FBN*2, high *IGF*2*BP*3, and low *PDE*1*C* expression
----------------------------------------------------------------------------------------------------

qRT-PCR was performed on 21 primary cell lines (17 craniosynostosis cases and 4 controls) that were identified in the microarray study to have high *FBN*2, high *IGF*2*BP*3, and low *PDE*1*C* levels (ie, female cases becoming male-like) ([Fig. 2](#f2-grsb-6-2012-081){ref-type="fig"} and [Supplemental Table 5](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). These samples were specifically chosen to investigate whether consistently convergent gene expression in craniosynostosis cases leads to dysregulation of *RUNX*2 expression/activity, due to the fact that the three genes are known to modulate its activity. First, convergent expression of *FBN*2*, IGF*2*BP*3*, PDE*1*C, RUNX*2, and *TINAGL*1 was confirmed in the selected cases by qRT-PCR, based on the fact that female and male cases showed no significant differences in the expression of these transcripts ([Supplemental Table 5](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). When compared to controls, qRT-PCR was unable to detect significant downregulation of *PDE*1*C* in cases suggesting concurrent upregulation of *FBN*2 and *IGF*2*BP*3 is more critical to the disease state. This was found to be true in that three-fold *FBN*2 upregulation and four-fold *IGF*2*BP*3 upregulation, in addition to nearly five-fold *TINAGL*1 downregulation were observed in cases compared to controls ([Table 4](#t4-grsb-6-2012-081){ref-type="table"}). Furthermore, qRTPCR not only confirmed that these same case lines expressed *RUNX*2 to a greater extent than matched controls, but also found this upregulation to be more than six-fold ([Table 4](#t4-grsb-6-2012-081){ref-type="table"}). These results suggests that the ↑*FBN*2*,* ↑*IGF*2*BP*3*,* ↓*TINAGL*1 transcriptomic signature represents a polygenic signature (and potential cause) of craniosynostosis that acts through cooperative *RUNX*2 upregulation.

Discussion
==========

Unlike the majority of syndromic forms, nonsyndromic craniosynostosis is much more common, is not associated with predictable non-calvarial phenotypic manifestations, and has unique sex-based frequencies depending on the suture that is prematurely fusing.[@b2-grsb-6-2012-081],[@b8-grsb-6-2012-081] One notable exception is the P250R fibroblast growth factor receptor 3 (FGFR3) mutation in Muenke syndrome, which is associated with a more severe phenotype in females compared to males.[@b14-grsb-6-2012-081] To investigate sex-based differences in the frequency of non-syndromic craniosynostosis, a unique comparative transcriptomic approach was developed to identify transcriptional changes driving sex predilection ([Fig. 1](#f1-grsb-6-2012-081){ref-type="fig"}). This model was necessary because there are sex specific effects differentially expressed among controls that are not related to craniosynostotic mechanisms (ie, genes on the sex chromosomes and those genes regulated by genes on the sex chromosomes). These normal differences need to be "removed" in order to understand sex related effects that are specific to the disease state. As proof of principle, our approach was internally validated by the fact that only sex-linked genes were identified in the shared region of the Venn diagrams ([Supplemental Table 3](#s1-grsb-6-2012-081){ref-type="supplementary-material"}).

Sex-related transcript expression that "diverged" in craniosynostotic individuals was dependent on the synostosis sub-type. In fact, extensive divergent expression was exclusive to metopic cases ([Table 1](#t1-grsb-6-2012-081){ref-type="table"}). It was expected that metopic and sagittal cases would share similar divergent gene expression profiles considering metopic and sagittal craniosynostosis not only have defined male to female ratios greater than 3:1, but also share many other epidemiological similarities.[@b8-grsb-6-2012-081] It is worth noting that expression of one transcript (*CD*24) was found to be divergent in both sagittal and metopic cases, suggesting that reduced levels of *CD*24 expression may be associated with developing craniosynostosis in females ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). In fact, recent evidence suggests that *CD*24 may inhibit cell invasiveness,[@b15-grsb-6-2012-081] suggesting that loss of *CD*24 expression may promote cell invasion, perhaps at the osteogenic front, and act as a mechanism for premature suture closure.

In males, divergent upregulation of *VCAM*1 was observed in coronal and metopic cases, but not in sagittal cases. However, both male and female sagittal cases had increased *VCAM*1 expression compared to their sex-matched controls ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). Even though *VCAM*1 expression was divergent in coronal and metopic cases and upregulated in all male cases compared to sex-matched controls, the increase seen in affected females with coronal and sagittal synostosis makes it unlikely that upregulation of this transcript is a male-specific effect. While male cases generally have higher *VCAM*1 levels than female cases, female coronal and sagittal cases still have higher *VCAM*1 expression than their sex-matched controls to a significantly large extent ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). These results suggest that while increased *VCAM*1 expression is related to craniosynostosis, its upregulation may be sex-independent. This observation substantiates an earlier report from our lab identifying *VCAM*1 upregulation as a novel biomarker in single-suture craniosynostosis.[@b16-grsb-6-2012-081]

Unlike divergent expression, convergent expression in craniosynostotic individuals was independent of the synostosis sub-type ([Table 2](#t2-grsb-6-2012-081){ref-type="table"}). Convergent transcripts were then mined to identify gene expression that was also significantly different between the cases and their sex-matched controls ([Supplemental Table 4](#s1-grsb-6-2012-081){ref-type="supplementary-material"}). Only three of the convergent transcripts were differentially expressed in all three synostosis sub-types and confirmed by qRT-PCR; *IGF*2*BP*3 and *FBN*2 in females, and *TINAGL*1 in males ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). Convergent expression of *IGF*2*BP*3 and *FBN*2 is interesting on two levels. First, gain of *IGF*2*BP*3 and *FBN*2 expression in female cases results in "male-like" expression of these transcripts ([Fig. 2](#f2-grsb-6-2012-081){ref-type="fig"}). The fact that males have a higher incidence for developing craniosynostosis would suggest that females with "male-like" expression of craniosynostosis-associated genes may have a higher risk of developing the disease. Second, increased *IGF*2*BP*3 and *FBN*2 expression in case females would have a the same effect on *RUNX*2 activity, a transcription factor that is expressed in fusing cranial sutures.[@b17-grsb-6-2012-081] Mutations of the *RUNX*2 modulator, *TWIST*1, are associated with a syndromic form of craniosynostosis known as Saethre-Chotzen syndrome.[@b18-grsb-6-2012-081] *TWIST*1 is a negative regulator of *RUNX*2, therefore loss of function mutations in *TWIST*1 lead to increased *RUNX*2 activity accounting for the presumed mechanism of action by which these mutations lead to non-syndromic craniosynostosis.[@b19-grsb-6-2012-081] This mechanism is consistent with the finding that duplication of the *RUNX*2 gene is associated with metopic craniosynostosis.[@b20-grsb-6-2012-081]

In osteoblasts, *RUNX*2 activation can also occur through Ca^2+^-mediated PI3K/Akt activation and subsequent *FOXO*1/4 phosphorylation.[@b21-grsb-6-2012-081],[@b22-grsb-6-2012-081] The male-like expression of *IGF*2*BP*3 and *FBN*2 in female craniosynostosis cases can impact this pathway at various points to promote *RUNX*2 activity ([Fig. 3](#f3-grsb-6-2012-081){ref-type="fig"}). Increased *IGF*2*BP*3 expression promotes IGF2 translation leading to PI3K/Akt-mediated *RUNX*2 activity.[@b23-grsb-6-2012-081] Upregulation of *FBN*2 has been shown to increase bone mass by restricting *RUNX*2 microRNA expression and processing, thereby attenuating the translational repression of *RUNX*2.[@b24-grsb-6-2012-081] Another mechanism by which increased *FBN*2 expression leads to increased *RUNX*2 activity is through the negative regulation of TGF-β signaling, a cascade known to repress *RUNX*2 activity.[@b25-grsb-6-2012-081],[@b26-grsb-6-2012-081] In fact, type 1 Loeys-Dietz syndrome, which is caused by mutations in TGF-β receptors, is associated with craniosynostotic phenotypes.[@b27-grsb-6-2012-081] Finally, high *FBN*2 expression may increase osteoblast migration, as alterations to intracellular Ca^2+^ levels have been shown to promote cell migration along fibrillin paths.[@b28-grsb-6-2012-081] Mutations in *FBN*2 cause congenital contractual arachnodactyly,[@b29-grsb-6-2012-081] and while there are currently no known *FBN*2 mutations that cause craniosynostosis, mutations in *FBN*1 cause Marfan Syndrome[@b30-grsb-6-2012-081] and possibly Shprintzen-Goldberg Syndrome,[@b31-grsb-6-2012-081],[@b32-grsb-6-2012-081] a syndromic form of craniosynostosis with Marfanoid features that is associated with arachnodactyly.[@b29-grsb-6-2012-081],[@b33-grsb-6-2012-081] The fact that alterations to *FBN*1 and *FBN*2 gene function lead to similar phenotypes, coupled with the fact that *FBN*1 and *FBN*2 share overlapping functionality,[@b24-grsb-6-2012-081],[@b34-grsb-6-2012-081] strongly implicates the role fibrillin dysregulation in the pathogenesis of craniosynostosis. Taken together, craniosynostosis cases with high *FBN*2 and *IGF*2*BP*3 expression compared to controls with high expression of these same transcripts demonstrated a six-fold increase in *RUNX*2 expression ([Table 3](#t3-grsb-6-2012-081){ref-type="table"}). This suggests that significantly high *FBN*2 and *IGF*2*BP*3 expression coupled with *RUNX*2 upregulation might act as a pathogenic mechanism for craniosynostosis ([Fig. 3](#f3-grsb-6-2012-081){ref-type="fig"}).

With respect to convergent expression that was differentially expressed between male cases and male controls, only *TINAGL*1 downregulation surfaced as a potential marker associated with all male forms of nonsyndromic craniosynostosis. *TINAGL*1 is a matricellular protein that has been shown to promote cell adhesion and invasion through its interactions with cell surface receptors and cell matrix proteins such as laminin and integrin α5-β1.[@b35-grsb-6-2012-081],[@b36-grsb-6-2012-081] Our previous findings implicating extracellular matrix-mediated focal adhesion as the strongest signal associated with non-syndromic craniosynostosis cases strongly supports the identification of *TINAGL*1 as a transcript associated with the disease state.[@b16-grsb-6-2012-081] Furthermore, *TINAGL*1 overexpression has been shown to couple TGF-β to SMAD2/3 phosphorylation in endothelial cells, a mechanism by which TGF-β attenuates *RUNX*2 function in osteoblasts.[@b37-grsb-6-2012-081],[@b38-grsb-6-2012-081] Presumably, lower levels of *TINAGL*1 observed in craniosynostotic males would lead to decreased TGF-β signaling through SMAD2/3, and increased *RUNX*2 function ([Fig. 3](#f3-grsb-6-2012-081){ref-type="fig"}).[@b37-grsb-6-2012-081],[@b38-grsb-6-2012-081] This mechanism is further supported by the fact that cases with high *FBN*2 and *IGF*2*BP*3 expression have low *TINAGL*1 levels in addition to high *RUNX*2 expression ([Table 4](#t4-grsb-6-2012-081){ref-type="table"}).

In conclusion, non-syndromic craniosynostosis is a complex disease with multiple causes, of which only a handful have been discovered. By utilizing this unique sex-based transcriptomic approach, our lab was able to generate novel candidate genes that predispose individuals to developing the disease state. Based on the likelihood that non-syndromic craniosynostosis is a polygenic disease, sub-populations within each synostosis sub-type are likely driving the significant changes in gene expression that surfaced using this approach. Finding commonality among these diverse targets is critical to understanding the mechanism by which premature fusion of calvarial sutures occurs. Our approach was able to identify convergent sex-based gene expression that cooperatively upregulates *RUNX*2 expression ([Table 4](#t4-grsb-6-2012-081){ref-type="table"}), implicating the ↑*FBN*2*,* ↑*IGF*2*BP*3*,* ↓*TINAGL*1 transcriptomic signature in the development of single-suture craniosynostosis. A potential limitation of this study is that while care was taken to age-match the case and control samples, the primary control lines in the entire cohort were generally from older children due to the limited availability of calvaria samples from controls less than one year of age.[@b16-grsb-6-2012-081] Future work will focus on large-scale sequencing of the candidates presented here, as well as any transcriptional regulators (promoter regions, transcription factors, nuclear receptors, etc.) in individuals that are known to have divergent/convergent transcriptomic profiles to identify causal mutations. The identification of transcripts associated with osteogenic differentiation and proliferation in this study suggests that these candidates are of interest, and that this novel approach has potential utility in the identification of gene candidates and transcriptomic signatures in other diseases with disparate sex-based frequencies.

Supplementary Information
=========================

###### 

**Supplementary Table 1**

(divergent): Expression of the 103 divergent transcripts differentially expressed to a large and significant extent between the sexes in craniosynostosis cases and not in controls.

**Supplementary Table 2**

Individual qRT-PCR data for *CD24* expression in randomly selected cases (n = 24) and controls (n = 8).

**Supplementary Table 3**

(shared): Expression of 21 shared transcripts differentially expressed to a large and significant extent between the sexes in both controls and craniosynostosis cases.

**Supplementary Table 4**

(convergent): Expression of 32 convergent transcripts differentially expressed to a large and significant extent between the sexes in controls and not in craniosynostosis cases.

**Supplementary Table 5**

Individual qRT-PCR data for cases and controls in which *FBN*2 and *IGF*2*BP*3 expression were both in the top third of the entire cohort (n = 249), while maintaining *PDE*1*C* expression within the bottom third.

**Author Contributions**

Conceived and designed the experiments: BDS, MLC. Analysed the data: BDS, SSP, RPB, TKB, MLC. Wrote the first draft of the manuscript: BDS. Contributed to the writing of the manuscript: BDS, RPB, MLC. Agree with manuscript results and conclusions: BDS, SSP, RPB, TKB, MLC. Jointly developed the structure and arguments for the paper: BDS, MLC. Made critical revisions and approved final version: BDS, SSP, MLC. All authors reviewed and approved of the final manuscript.

**Disclosures and Ethics**

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest.

**Funding**

Statement of financial support: This work was supported by NIH grants NIH/NIDCR R01 DE018227, NIH/NIEHS P30ES07033, NIH/NICHD P30HD02274 and the Jean Renny Endowment for Craniofacial Research.

![Comparative approach used to identify transcripts that may predispose individuals to non-syndromic craniosynostosis based on sex.\
**Notes:** Sex-based differences associated with affected individuals and not seen in controls are contained within the divergent gene set, whereas sex-based differences unique to the control population and not seen in affected individuals are contained within the convergent gene set. Those transcripts contained within the shared gene set are sex-based differences associated with both controls and affected craniosynostosis cases. Once identified, gene expression considered divergent or convergent was reanalyzed by comparing affected individuals to their respective sex-matched controls.](grsb-6-2012-081f1){#f1-grsb-6-2012-081}

![Consistently convergent gene expression.\
**Notes:** Convergent transcripts were defined as those genes that were differentially expressed between male and female controls (\|fold change\| \>1.5, *P* \< 0.05), but lost these sex-related differences when male and female cases were compared. Four genes fit these criteria and were consistent in all three synostosis sub-types (coronal, metopic and sagittal) to a large and significant extent.](grsb-6-2012-081f2){#f2-grsb-6-2012-081}

![Proposed *RUNX*2 activation model for differentially expressed convergent transcripts.](grsb-6-2012-081f3){#f3-grsb-6-2012-081}

###### 

Number of divergent, shared, and convergent transcripts identified based on craniosynostosis sub-type (gene symbols for the transcripts represented here are listed in [Table 2](#t2-grsb-6-2012-081){ref-type="table"}).

             Transcripts in divergent gene set   Transcripts in shared gene set   Transcripts in convergent gene set
  ---------- ----------------------------------- -------------------------------- ------------------------------------
  Coronal    6                                   21                               31
  Metopic    99                                  21                               31
  Sagittal   1                                   20                               32

###### 

Divergent, shared and convergent transcripts that underwent large (\|log2FC\| \>1.5) and significant (*P* \< 0.05) changes when comparing either male and female craniosynostosis cases directly or male and female control populations directly.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Divergent gene set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Shared gene set                                                                                                                                                                                               Convergent gene set
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Coronal cases (6):***CDH6, FAM38B, NEFM, OGN, S*100*A*4*, VCAM*1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **All cases (20):***BPY2, CYorf15A, CYorf*15*B, DDX*3*Y, EIF*1*AY, GAGE*12*C, KDM*5*D, JPX, TTTY*14*, NLGN*4*Y, PRKY, RBMY*1*A*1*, RBMY*1*B, RBMY*2*EP, RPS*4*Y*1*, RPS*4*Y*2*, TSPY*1*, USP*9*Y, UTY, ZFY*   **All cases (30):***ACAN, ACTG*2*, CNTNAP*3*, CHI*3*L*1*[a](#tfn2-grsb-6-2012-081){ref-type="table-fn"}, COL*4*A*1*, COL*4*A*2*, DSG*2*[b](#tfn3-grsb-6-2012-081){ref-type="table-fn"}, ENPP*2*, FBN*2*, FGL*2*, FLT*1*, GCNT*4*, GFRA*1*, GREM*2*, ID*4*, IGF*2*BP*3*, LAMC*2*, LOXL*4*, LPPR*4*, LUZP*2*, MCAM, MYOCD, OXTR, PDE*1*C, PENK, PLA*2*G*5*, SEMA*3*C, SEMA*3*D, SFRP*4*, SLC*7*A*2*, SULT*1*E*1*, TINAGL*1
  **Metopic cases (99):***ABCA*8*, ADAMTS*5*, ADAMTSL*3*, AK*5*, ANLN, ARHGAP*11 *A, ARHGDIB, ASPM, AURKA, BRIP*1*, BUB*1*, BUB*1*B, CA*12*, CASC*5*, CCNA*2*, CCNB*1*, CCNB*2*, CCNE*2*, CD*24*, CDC*2*, CDC*20*, CDCA*2*, CDKN*3*, CENPF, CENPI, CEP*55*, CLDN*1*, CLDN*11*, COL*11*A*1*, COL*14*A*1*, CRISPLD*1*, CTSC, CYTL*1*, DEPDC*1*, DLGAP*5*, DTL, ESCO*2*, EXO*1*, EYA*4*, F*2*R, F*2*RL*2*, FAM*111*B, FAM*38*B, FLG, FNDC*1*, HAPLN*1*, HELLS, HEY*2*, HIST*1*H*1*B, HIST*1*H*2*BM, HIST*1*H*3*B, HJURP, HMCN*1*, HMMR, IFI*30*, KIAA*0101*, KIF*11*, KIF*14*, KIF*15*, KIF*20*A, KIF*20*B, KIF*2*C, LMNB*1*, LOC*100289612*, MELK, MKI*67*, MOXD*1*, MXRA*5*, MYCT*1*, NCAPG, NEIL*3*, NUF*2*, NUSAP*1*, PAMR*1*, PBK, PLA*2*G*16*, PLK*1*, PLK*4*, PLXDC*2*, PRC*1*, PRR*11*, PTGER*2*, PTTG*1*, RAD*51*AP*1*, RRM*2*, SCRG*1*, SGCG, SGOL*1*, SHCBP*1*, SKA*1*, SKA*3*, SLITRK*6*, SPC*25*, SULF*2*, TOP*2 *A, TRIP*13*, TTK, VCAM*1*, ZIC*1\                                                                                                                                                                                                                 
  **Sagittal cases (1):***CD24*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Convergent *CHI3*L1 expression was observed in metopic and sagittal cases only;

Convergent *DSG*2 expression was observed in coronal and sagittal cases only.

###### 

Genes differentially expressed between all affected males or all affected females compared to their sex-matched controls (\|% change\| \>50%, *P* \< 0.05).

  Transcript   Gene set     Female_male (% change)   Female_female (% change)                             Male_male (% change)                                          
  ------------ ------------ ------------------------ ---------------------------------------------------- ---------------------- ----- ------ ----- ----- ------ ------ -----
  *FBN*2       Convergent   −76                      --                                                   --                     --    95     107   57    --     --     --
  *IGF2BP*3    Convergent   −88                      --                                                   --                     --    88     157   88    --     --     --
  *PDE*1*C*    Convergent   74                       --                                                   --                     --    −108   −96   −54   --     --     --
  *TINAGL*1    Convergent   −71                      --                                                   --                     --    --     --    --    −113   −108   −52
  *CD*24       Divergent    --                       −49[a](#tfn5-grsb-6-2012-081){ref-type="table-fn"}   −56                    −75   --     −76   −95   --     --     --
  *VCAM*1      Divergent    --                       −64                                                  −55                    --    78     --    141   103    61     85

**Note:**

Significant difference, but below % change threshold value.

###### 

qRT-PCR validation of differential expression between craniosynostosis cases and controls both concurrently expressing the high *FBN*2, high *IGF*2*BP*3 and low *PDE*1*C* (*P* \< 0.05).

  ---------------------------------------------------------------------------
  Transcript    Case_control (fold change)   Primers
  ------------- ---------------------------- --------------------------------
  *FBN*2        3.2                          *fwd:* CTGAAGGCGGGTTTCTAGCG\
                                             *rvs:* CAAATCGGGACAATGCACTGG

  *IGF*2*BP*3   4.5                          *fwd:* TATATCGGAAACCTCAGCGAGA\
                                             *rvs:* GGACCGAGTGCTCAACTTCT

  *RUNX*2       6.5                          *fwd:* TGGTTACTGTCATGGCGGGTA\
                                             *rvs:* TCTCAGATCGTTGAACCTTGCTA

  *TINAGL*1     −4.8                         *fwd:* ATGGGACCCACTCAGTCAAGA\
                                             *rvs:* GTTGGCCGCAGTCCAGTATTT
  ---------------------------------------------------------------------------
